Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer's disease

大量任命行业和学术专家，以支持ASN51在阿尔茨海默氏病中的II期开发

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB). These include Dr Samantha Budd Haeberlein, PhD, Henrik Zetterberg, MD, PhD, Rik Ossenkoppele, PhD, and Christopher van Dyck, MD..

瑞士洛桑和旧金山，2024年3月6日/PRNewswire/-Asceneuron SA，一家致力于针对神经退行性疾病根本原因的临床阶段生物技术公司，今天宣布任命神经退行性疾病专家为其科学咨询委员会（SAB）。其中包括Samantha Budd Haeberlein博士、Henrik Zetterberg博士、Rik Ossenkoppele博士和Christopher van Dyck博士。。

Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease. This compound is a potential best-in-class, orally administered, OGA inhibitor targeting tau aggregation. The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development..

Asceneuron正在将其主要资产ASN51的开发推进针对阿尔茨海默氏病的II期临床开发。该化合物是一种潜在的同类最佳口服OGA抑制剂，靶向tau聚集。科学顾问委员会成员在临床试验设计和生物标志物方面拥有丰富的经验，并将通过II期临床开发帮助支持这一有前途的计划。。

ASN51 has demonstrated its potential as a pathbreaker to halt disease progression in tau-mediated neurodegenerative diseases with its safe and well tolerated profile and sustained high central enzyme occupancy. In the field of Alzheimer's disease, ASN51 has the potential to change the treatment paradigm for patients when it commences a Phase II clinical trial in the second half of 2024..

ASN51以其安全且耐受性良好的特性和持续的高中枢酶占有率，证明了其作为阻断tau介导的神经退行性疾病疾病进展的途径的潜力。在阿尔茨海默病领域，ASN51有可能在2024年下半年开始II期临床试验时改变患者的治疗模式。。

Ryan Schubert, Senior Vice President Research and Development at Asceneuron, said: 'There is strong momentum in the Alzheimer's disease field, driven by recent progress and developments. This is an exciting stage for Asceneuron as tau is now clinically validated as a target. Our once daily, orally administered anti-tau O-GlcNAcase inhibitor, ASN51, has the potential to be best in class based on its unique pharmacology.

Asceneuron研究与开发高级副总裁瑞安·舒伯特（RyanSchubert）说：“阿尔茨海默病领域有着强劲的势头，这是由最近的进展和发展所驱动的。对于Asceneuron来说，这是一个令人兴奋的阶段，因为tau现在已被临床验证为靶标。我们每天一次口服抗tau O-GlcNAcase抑制剂ASN51，基于其独特的药理学，有可能成为同类中最好的。

I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development. Their deep knowledge and expertise will be invaluable as we move ASN51 into Phase II development.'.

我很荣幸有这些神经退行性疾病专家在发展的关键时刻加入我们的SAB。随着ASN51进入第二阶段开发，他们的深厚知识和专业技能将是无价的。”。

Dr Samantha Budd Haeberlein, PhD, is an esteemed figure in neurological drug development with international experience at research and executive levels in the discovery and development of therapeutics and biomarkers for neurodegenerative diseases. She was previously Senior Vice President and Head of Neurodegeneration at Biogen, where she led and co-led the development of two FDA approved treatments for Alzheimer's disease, ADUHELM and LEQEMBI.

Samantha Budd Haeberlein博士是神经药物开发领域备受尊敬的人物，在神经退行性疾病的治疗和生物标志物的发现和开发方面具有国际研究和执行层面的经验。她曾任Biogen高级副总裁兼神经退行性疾病主管，领导并共同领导了两种FDA批准的阿尔茨海默病治疗药物ADUHELM和LEQEMBI的开发。

Samantha currently serves as the Chief Medical Officer at Enigma Biomedical Group, developing solutions for the treatment of neurodegenerative diseases, is on the Board of Directors at Vigil Neuro, and is a Senior Advisor to the ICG Life Sciences Investment team..

Samantha目前担任Enigma Biomedical Group的首席医疗官，开发治疗神经退行性疾病的解决方案，是Vigil Neuro的董事会成员，也是ICG生命科学投资团队的高级顾问。。

Henrik Zetterberg, MD, PhD, is a decorated researcher in the field of neurodegenerative diseases. Henrik is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London (UCL), UK, and is a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden.

Henrik Zetterberg，医学博士，博士，是神经退行性疾病领域的荣誉研究员。亨里克是瑞典哥德堡大学和英国伦敦大学学院（UCL）的神经化学教授，也是瑞典哥德堡萨尔格伦斯卡大学医院的临床化学家。

He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL, and is a Key Member of the Hong Kong Center for neurodegenerative diseases. He is also a Visiting Professor in the UW Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin..

他是哥德堡大学精神病学和神经化学系主任，领导伦敦大学学院英国DRI流体生物标志物实验室，也是香港神经退行性疾病中心的关键成员。他还是威斯康星州麦迪逊市医学与公共卫生学院西澳大学医学系的客座教授。。

Henrik has developed and researched new diagnostic tests and new preclinical models for Alzheimer's disease and has been recognised for his influential discoveries as a recipient of numerous prizes such as the Erik K. Fernström Prize for Junior Scientists and the Inga Sandeborg Prize for Research on Alzheimer's Disease..

亨里克已经开发和研究了阿尔茨海默病的新诊断测试和新的临床前模型，并因其有影响力的发现而被认可为众多奖项的获得者，例如埃里克·K·弗恩斯特伦初级科学家奖和因加·桑德伯格阿尔茨海默病研究奖。。

Rik Ossenkoppele, PhD, is a renowned academic in neuroscience, working at the intersection of neuroimaging, biomarkers, and cognition in Alzheimer's disease. Rik is an Associate Professor in Translational Neuroscience and is a Principal Investigator both at the Alzheimer center Amsterdam of the Amsterdam UMC and at Lund University in Sweden.

Rik Ossenkoppele博士是神经科学领域的著名学者，致力于阿尔茨海默病的神经影像学，生物标志物和认知的交叉。Rik是转化神经科学的副教授，也是阿姆斯特丹大学医学会阿姆斯特丹阿尔茨海默病中心和瑞典隆德大学的首席研究员。

Rik received the European Grand Prix for Research on the Foundation of Alzheimer's Disease in 2019, the Young Investigator Research award from Alzheimer Nederland in 2020, and the Queen Silvia Research prize in 2021..

Rik于2019年获得了欧洲阿尔茨海默氏病基础研究大奖赛，2020年获得了荷兰阿尔茨海默氏病青年研究员研究奖，2021年获得了西尔维亚女王研究奖。。

Christopher van Dyck, MD, is a leading clinical researcher focusing on neuroimaging and therapeutic studies of Alzheimer's disease and brain aging. He is a Professor of Psychiatry, Neurology, and Neuroscience and serves as Director of the Alzheimer's Disease Research Unit, the Alzheimer's Disease Research Center, and the Division of Aging and Geriatric Psychiatry at Yale School of Medicine..

克里斯托弗·范·戴克医学博士是一位领先的临床研究人员，专注于阿尔茨海默病和大脑衰老的神经影像学和治疗研究。他是精神病学、神经病学和神经科学教授，现任耶鲁大学医学院阿尔茨海默病研究室、阿尔茨海默病研究中心以及衰老和老年精神病学系主任。。

Alongside his academic positions, Christopher has extensive experience in leading and participating in more than 100 therapeutic trials in Alzheimer's disease, which include prodromal/ preclinical and brain aging stages. He serves on the Steering and Executive Committee and Co-Chairs the Protocol Evaluation Committee at the Alzheimer's Clinical Trials Consortium (ACTC).

除了他的学术职位外，克里斯托弗在领导和参与100多项阿尔茨海默病治疗试验方面拥有丰富的经验，这些试验包括前驱/临床前和大脑衰老阶段。他是阿尔茨海默病临床试验协会（ACTC）指导和执行委员会的成员，也是方案评估委员会的联合主席。

His extensive research has culminated in the lead authorship of the publication of the first disease-modifying treatment for AD (lecanemab) in 2023..

他的广泛研究最终于2023年发表了第一个AD疾病缓解治疗（lecanemab）的主要作者。。

About Asceneuron

关于Asceneuron

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The company's pipeline reflects its ambition and commitment to developing treatments for a wide a range of neurodegenerative diseases including Alzheimer's and Parkinson's disease, as well as orphan tauopathies.

Asceneuron是一家临床阶段的生物技术公司，专注于开发口服生物可利用疗法，用于治疗未满足医疗需求的神经退行性疾病。该公司的管道反映了其雄心壮志和承诺，即开发多种神经退行性疾病的治疗方法，包括阿尔茨海默氏病和帕金森氏病，以及孤儿tauopathies。

Asceneuron has two clinical-stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies: OGA inhibitor ASN90 (licensed to Ferrer Pharmaceuticals) for the treatment of progressive supranuclear palsy (PSP) and a potential best-in-class OGA inhibitor, ASN51 for Alzheimer's disease.

Asceneuron正在开发两种用于治疗蛋白病的临床阶段小分子O-GlcNAcase抑制剂：用于治疗进行性核上性麻痹（PSP）的OGA抑制剂ASN90（授权给Ferrer Pharmaceuticals）和潜在的同类最佳OGA抑制剂ASN51用于阿尔茨海默氏病。

Asceneuron is backed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com..

Asceneuron由著名的投资者财团支持，该财团由Sofinnova Partners、M Ventures、SR One、Johnson&Johnson Innovation–JJDC，Inc.（JJDC）和Kurma Partners组成。有关更多信息，请访问www.asceneuron.com。。

SOURCE Asceneuron

来源：Asceneuron